BACE2 and type 2 diabetes mellitus: While BACE2 inhibition for T2DM has a longer way to go before clinical proof-of-concept, a review of recent patent publications indicates pharmaceutical company discovery programs for this indication have been running since 2010 (Southan, 2013).